Core Viewpoint - Eli Lilly's MuFenda® (Tirzepatide injection multi-dose pen) has been launched online on JD Health, marking a significant advancement in the treatment of type 2 diabetes and long-term weight management, leveraging its unique dual-action mechanism and efficacy [1][2]. Group 1: Product Launch and Features - MuFenda® is the first and only GIP/GLP-1 receptor agonist approved for type 2 diabetes and long-term weight management globally [1]. - The new multi-dose pen design incorporates an innovative "4-dose integration," allowing patients to use one dose per week, fulfilling a month's treatment needs [1]. - The pen can be stored at room temperature (not exceeding 30°C) for 30 days after the first use, enhancing convenience for patients [1]. Group 2: Patient Experience and Accessibility - The multi-dose pen is designed for ease of use, with simple steps for loading the needle, expelling air, adjusting the dose, and injecting, which improves patient comfort [2]. - JD Health expressed enthusiasm for collaborating with Eli Lilly to introduce MuFenda® multi-dose pen, aiming to enhance the purchasing experience for patients [2]. - The launch on JD Health is expected to benefit more patients with type 2 diabetes and obesity, promoting healthier lifestyles [2].

本报讯(记者袁传玺) 日前，礼来制药旗下穆峰达(替尔泊肽注射液多剂量预装笔)在京东健康股份有限公司(以下简称"京东健 康")线上首发。穆峰达作为全球首个且目前唯一获批用于2型糖尿病和长期体重管理的GIP/GLP-1受体激 动剂，自上市以来便以其独特的双重作用机制和显著的疗效，赢得了广大患者的信赖与好评。此次替尔 泊肽注射液多剂量预装笔，是礼来制药推出的新型注射装置，将为患者带来全新的选择。 京东健康相关负责人表示："我们非常高兴能够与礼来制药合作，率先引入穆峰达多剂量预装笔。这款 改进剂型将在京东买药秒送独家首发，并同步在京东买药上线，给患者带来更加方便、快捷的购买体 验。未来，我们将继续与全球药企紧密合作，共同推动新特药的普及和可及性，为更多患者提供精准、 高效的治疗方案。" 随着穆峰达多剂量预装笔在京东健康平台的线上首发，相信将有更多2型糖尿病和肥胖患者从中受益， 实现更加健康、美好的生活。 此次，礼来制药改进了穆峰达的注射装置。穆峰达(替尔泊肽注射液多剂量预装笔)采用了创新的"4剂集 成"设计，每支笔包含四个固定剂量，每周使用一个剂量，即可满足患者一个月的治疗需求。这一设计 不仅简化了用药流程，减少了患 ...

Group 1 - The core viewpoint of the article highlights the launch of Eli Lilly's Mounjaro® (tirzepatide injection multi-dose prefilled pen) on JD Health, marking it as the first and only GIP/GLP-1 receptor agonist approved for type 2 diabetes and long-term weight management [1][2] - Mounjaro® features an innovative "4-dose integration" design, allowing patients to use one fixed dose per week, thus simplifying the medication process and improving adherence [1] - The multi-dose prefilled pen can be stored at room temperature not exceeding 30°C for 30 days after the first use, enhancing convenience for patients during travel or daily use [1] Group 2 - The user experience of Mounjaro® multi-dose prefilled pen is emphasized, with simple operation steps and a fine needle that reduces pain during injection, improving patient comfort [2] - JD Health expresses excitement about collaborating with Eli Lilly to exclusively launch Mounjaro® on their platform, aiming to enhance accessibility and convenience for patients [2] - The launch of Mounjaro® is expected to benefit more patients with type 2 diabetes and obesity, promoting healthier lifestyles [2]